Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Minlei Liao"'
Autor:
Zhaoqiang Cui, Zhaohui Qiu, Wenli Cheng, Wei Hu, Genshan Ma, Xiaojun Cai, Yafei Jin, Yi Zhao, Liqun He, Ying Li, Peili Bu, Xiaoping Chen, Ruxing Wang, Lin Chen, Peng Dong, Liuliu Feng, Xuebin Han, Mei Hong, Yinglong Hou, Minlei Liao, Mingliang Wang, Xiaoyan Wang, Jianhong Xie, Yawei Xu, Zhenxing Wang, Kai Huang, Yongle Li, Dongsheng Li, Xiaojun Ji, Jing Huang, Jun Wang, Danhong Fang, Jian'an Wang, Lijiang Tang, Yingwu Liu, Guosheng Fu, Juan Du, Ling Wang, Mengqi Liu, Junbo Ge
Publikováno v:
The Journal of Clinical Hypertension, Vol 26, Iss 1, Pp 5-16 (2024)
Abstract There lacks real‐world study with a large sample size assessing olmesartan medoxomil‐amlodipine besylate (OM‐AML) tablet. Therefore, this study aimed to evaluate the efficacy and safety of OM‐AML tablet in patients with essential hyp
Externí odkaz:
https://doaj.org/article/8d675c93ba9d40cfa31c783badc02596
Autor:
Zhenzhou Zhang, Mengshi Xie, Xixi Dai, Zhiyong Duan, Zhiren Lu, Liangyin Cai, Rongrong Gu, Lei Shen, Zhong Xu, Weifeng Yao, Yunfei Liu, Minlei Liao, Hongyu Shi
Publikováno v:
Heliyon, Vol 9, Iss 6, Pp e17464- (2023)
Objective: This study aims to investigate the prognostic value and economic benefit of coronary angiography-derived fractional flow reserve (caFFR) guided percutaneous coronary intervention (PCI) in patients with coronary artery disease. Methods: All
Externí odkaz:
https://doaj.org/article/a44c1f9e1a984f998e22b576c5b22bfb
Autor:
Lynley V. Marshall, Katherine E. Hutchinson, Jean Michon, Minlei Liao, H.N. Caron, Colby S. Shemesh, Michela Casanova, Gianluca Rossato, Mufiza Farid-Kapadia, Nadège Corradini, Francis Donaldson, C. Michel Zwaan, Tanya M. Trippett, Birgit Geoerger, Franck Bourdeaut
Publikováno v:
Lancet Oncology, 21(1), 134-144. Lancet Publishing Group
Atezolizumab is an inhibitor of PD-L1, which can lead to enhanced anticancer T-cell activity. We aimed to evaluate the safety, pharmacokinetics, and activity of atezolizumab in children and young adults with refractory or relapsed solid tumours, with
Autor:
Gianluca Rossato, Francis Donaldson, Jean Michon, Lynley V. Marshall, Nadège Corradini, C. Michel Zwaan, Colby S. Shemesh, H.N. Caron, Franck Bourdeaut, Katherine E. Hutchinson, Tanya M. Trippett, Michela Casanova, Minlei Liao, Birgit Geoerger, Mufiza Farid-Kapadia
Publikováno v:
SSRN Electronic Journal.
Background: Atezolizumab targets programmed death-ligand 1 (PD-L1), leading to enhanced anticancer T-cell activity. The iMATRIX-atezolizumab study (phase 1/2, multicentre, open-label; NCT02541604) is the first trial to evaluate the safety, pharmacoki
Publikováno v:
The Journal of Rheumatology. 43:88-96
Objective.Direct costs of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) have not been well characterized in the United States. This study assessed healthcare resource use and direct cost of AS and PsA, and identified predictors of all-cau
Publikováno v:
Journal of Dermatological Treatment. 26:514-519
Pain, itching, burning and irritation are common symptoms of psoriasis but have not been well characterized by overall psoriasis severity.Using 2012 syndicated psoriasis patient survey data, 1050 subjects were classified into mild (n = 610) and moder
Autor:
Francis Donaldson, Tanya M. Trippett, Mufiza Farid-Kapadia, C. Michel Zwaan, Lingyan Helen Fu, Minlei Liao, Birgit Geoerger, Katherine E. Hutchinson, Lynley V. Marshall, Nga Wan Rachel Tam, Gianluca Rossato, Meghna Das Thakur
Publikováno v:
Cancer Research. 79:3114-3114
Introduction The iMATRIX-atezo trial (NCT02541604) assessed the safety and pharmacokinetics (primary objectives) and preliminary activity (secondary objective) of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumor
Publikováno v:
BMC Nephrology
Background Cluster analysis (CA) is a frequently used applied statistical technique that helps to reveal hidden structures and “clusters” found in large data sets. However, this method has not been widely used in large healthcare claims databases
Publikováno v:
Rheumatology: Current Research.
Objective: Limited information exists on real-world use of anti-tumor necrosis factor-α (TNFα) biologic agents in ankylosing spondylitis (AS). This study evaluated the treatment patterns and costs of anti-TNFα biologic therapy and disease-modifyin
Publikováno v:
Psoriasis Forum. :7-7